News

Results EIC Pathfinder / FETPROACT-EIC-07-2020 and FETPROACT-EIC-08-2020 - cut-off date: 02/07/2020

Published on | 4 years ago

Programmes FET EIC Pilot

The number of proposals that was submitted for the calls FETPROACT-EIC-07-2020 and FETPROACT-EIC-08-2020 was in total 236 - 149 proposals for 07 and 87 for 08 – of which 18 proposals are eligible for funding – 13 for 07 and 5 for 08. Under these 18 proposals are four with a Flemish partner:

  • IMEC, partner in project “DIGIPREDICT - Edge AI-deployed DIGItal Twins for PREDICTing disease progression and need for early intervention in infectious and cardiovascular diseases beyond COVID-19”
  • Universiteit Antwerpen, partner in project “EBEAM - Electron beams enhancing analytical microscopy”
  • Tenneco Automotive Europe BVBA, partner in project “Electro-Intrusion - Simultaneous transformation of ambient heat and undesired vibrations into electricity via nanotriboelectrification during non-wetting liquid intrusionextrusion into-from nanopores”
  • Katholieke Universiteit Leuven, partner in project “HYSOLCHEM - A Hybrid Reactor for Solar CO2 and N2 Conversion Coupled to WasteWater Treatment”

An overview of the funded proposals, their consortium partners and allocated budgets

European Commission press release

Related news article

Number of proposals submitted - FETPROACT-EIC-07-2020 and FETPROACT-EIC-08-2020

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1683 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.